Clinical Trial Update: Safety and Efficacy of Berodual® Inhaled Via Respimat® Compared to MDI (Metered Dose Inhaler) in Pediatric Patients With Asthma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating the safety and efficacy of Berodual inhaled via Respimat compared with a metered-dose inhaler in pediatric asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Berodual (ipratropium bromide + fenoterol)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Asthma | Phase 3 | Status: COMPLETED